HOHL BENJAMIN (CHIEF FINANCIAL OFFICER) sold 13.1% of their position (6.02K shares) of ENLIVEN THERAPEUTICS, INC. on the open market
Open‑market sale worth $352.6K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 8/19/2026ACC: 0001882764-26-000007
Officer· CHIEF FINANCIAL OFFICER
Since Feb 2026
-6.02K
Net shares
Net seller
$352.6K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
6.02K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−4.63K
Price / share
$58.35
Trade value
$270.17K
% of position
10.1%
8/17/2026
46.05K→41.42K
Common Stock
Direct
Shares
−1.39K
Price / share
$59.35
Trade value
$82.38K
% of position
3.4%
8/17/2026
41.42K→40.04K
Total
Net shares
−6.02K
Net value
-$352.55K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/17/2026 | S · Sale | −4.63K | $58.35 | $270.17K | 10.1% | 46.05K | 41.42K |
| Common Stock Direct | 8/17/2026 | S · Sale | −1.39K | $59.35 | $82.38K | 3.4% | 41.42K | 40.04K |
| Total | −6.02K | -$352.55K | ||||||
Derivative Transactions0
No derivative transactions reported